Milestone Pharmaceuticals Inc. announced an investor event on February 25, 2025, in New York to discuss its commercial launch plan for etripamil nasal spray, also known as CARDAMYST™, which is ...

MONTREAL and CHARLOTTE, N.C., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that President and CEO, Joe Oliveto, will present at the TD Cowen 45 th ...

Milestone’s NDA for CARDAMYST is currently under review at the FDA with a Prescription Drug User Fee Act (PDUFA) target date of March 27, 2025. The Company continues to advance commercial preparations ...

Milestone's lead investigational product is etripamil, a novel calcium channel blocker nasal spray that is being studied for patients to self-administer without medical supervision to treat ...

Milestone Pharmaceuticals Inc. announced that the PDUFA date for its nasal spray CARDAMYST™ (etripamil) for treating Paroxysmal Supraventricular Tachycardia (PSVT) has been set for March 27 ...

Milestone Pharmaceuticals ... short-acting calcium channel blocker that is designed as a rapid-onset nasal spray to be self-administered by patients. It develops etripamil to treat paroxysmal ...

Rodman & Renshaw launched its coverage of Canadian biopharma Milestone Pharmaceuticals (NASDAQ ... lead candidate Cardamyst ...

Milestone Pharmaceuticals Inc. ( NASDAQ:MIST ) is possibly approaching a major achievement in its business, so we would... - PDUFA date of March 27, 2025 for CARDAMYST™ (etripamil) nasal spray ...

Etripamil is Milestone's lead investigational product. It is a novel calcium channel blocker nasal spray under clinical development for frequent and often highly symptomatic episodes of PSVT and ...

Milestone's lead investigational product is etripamil, a novel calcium channel blocker nasal spray that is being studied for patients to self-administer without medical supervision to treat ...